scPharmaceuticals Inc
SCPH5.245USD
+0.075+1.45%
Market hours （ET）Quotes delayed by 15 min
263.74MMarket Cap
LossP/E TTM
More Details of scPharmaceuticals Inc Company
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Company Info
Ticker SymbolSCPH
Company namescPharmaceuticals Inc
IPO dateNov 17, 2017
CEOMr. John H. Tucker
Number of employees162
Security typeOrdinary Share
Fiscal year-endNov 17
Address25 Burlington Mall Road, Suite 203
CityBURLINGTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code01803
Phone16175170730
Websitehttps://www.scpharmaceuticals.com/
Ticker SymbolSCPH
IPO dateNov 17, 2017
CEOMr. John H. Tucker
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John H. Tucker
Mr. John H. Tucker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
122.34K
-55.88%
Mr. Leonard D. Schaeffer
Mr. Leonard D. Schaeffer
Independent Director
Independent Director
111.90K
--
Ms. Rachael Nokes
Ms. Rachael Nokes
Chief Financial Officer
Chief Financial Officer
30.39K
-71.18%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Jack A. Khattar
Mr. Jack A. Khattar
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Klaus Veitinger, M.D., Ph.D.
Dr. Klaus Veitinger, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William T. Abraham, M.D.
Dr. William T. Abraham, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John H. Tucker
Mr. John H. Tucker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
122.34K
-55.88%
Mr. Leonard D. Schaeffer
Mr. Leonard D. Schaeffer
Independent Director
Independent Director
111.90K
--
Ms. Rachael Nokes
Ms. Rachael Nokes
Chief Financial Officer
Chief Financial Officer
30.39K
-71.18%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
11.48%
Rubric Capital Management LP
9.04%
Luther King Capital Management Corp.
6.95%
Lytton (Laurence W)
5.58%
AIGH Capital Management, LLC.
5.49%
Other
61.45%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
11.48%
Rubric Capital Management LP
9.04%
Luther King Capital Management Corp.
6.95%
Lytton (Laurence W)
5.58%
AIGH Capital Management, LLC.
5.49%
Other
61.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
26.77%
Private Equity
17.92%
Hedge Fund
15.19%
Investment Advisor/Hedge Fund
11.23%
Individual Investor
6.08%
Research Firm
3.79%
Venture Capital
2.27%
Bank and Trust
0.15%
Pension Fund
0.03%
Other
16.57%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
207
44.05M
83.43%
-9.61M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
2023Q2
160
30.81M
85.97%
-2.10M
2023Q1
135
26.76M
76.80%
-865.96K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
6.06M
11.48%
--
--
Mar 31, 2025
Rubric Capital Management LP
4.78M
9.04%
--
--
Mar 31, 2025
Luther King Capital Management Corp.
3.12M
5.91%
+263.26K
+9.21%
Mar 31, 2025
Lytton (Laurence W)
2.94M
5.58%
+1.12M
+61.35%
Sep 30, 2024
AIGH Capital Management, LLC.
3.10M
5.86%
--
--
Mar 31, 2025
Lundbeckfond Invest
2.86M
5.42%
+2.86M
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.15M
4.08%
+43.64K
+2.07%
Mar 31, 2025
The Vanguard Group, Inc.
1.99M
3.77%
-115.70K
-5.49%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.65M
3.12%
-29.52K
-1.76%
Mar 31, 2025
Rice Hall James & Associates, LLC
1.40M
2.65%
+408.42K
+41.27%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.47%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 3000 ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.47%
iShares Micro-Cap ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 3000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
